This article describes how high-performing antibody solutions are developed and how they can speed up both research and diagnostic protocols.
Developing Custom Monoclonal Antibodies
Abcam has a range of antibodies designed to maximize the likelihood of success in research and diagnosis; from recombinant antibodies that can detect new biomarkers, to antibodies that have performed consistently with high degrees of sensitivity in diagnostic tests.
Abcam’s Unique Advantages
Abcam has a long and trusted record in producing antibodies designed to bind to a large variety of specific protein targets across a broad range of research areas, and in applications such as IHC and CYTOF.
Abcam’s discovery platform boasts an IP that makes it easy to take the same clone being validated in the lab into a clinical setting.
For rapid and reliable screening, Abcam has the tools to provide users with assay cascades to perform custom library screening. Other features include HTRF, fluorescence assays, IC50, PK/PD, functional assays and reporter assays.
The Abcam team has extensive industry experience, which means that users can get support at any stage of the program. From antigen design to the supply of GMP/IVD - Abcam will take care of everything.
Abcam follows a tried-and-tested multiplatform approach that includes the proprietary NGS-rabbit monoclonal platform.
Confidentiality is of great importance to Abcam. When designing and providing customized solutions, Abcam deals with many commercial partners that have technologies and projects that need to be kept confidential. For this reason, Abcam has put in place multiple firewalls and protective devices to keep its partners and their projects strictly private.
Abcam is a global life sciences company providing highly validated antibodies and other binders and assays to the research and clinical communities to help advance the understanding of biology and causes of disease.
Abcam’s mission is to serve life scientists to help them achieve their mission faster by listening to their needs, continuously innovating and improving and by giving them the tools, data and experience they want. Abcam’s ambition is to become the most influential life science company for researchers worldwide.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.